ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine[1].
